Literature DB >> 11839465

Sensitivity and specificity of carbohydrate-deficient transferrin in drinking experiments and different patients.

H Walter1, I Hertling, N Benda, B König, K Ramskogler, A Riegler, B Semler, A Zoghlami, O M Lesch.   

Abstract

Information provided by patients about the amounts of alcohol they drink may often be too subjective and therefore unreliable. Because of the possible serious consequences of interactions between alcohol and medication, reliable laboratory test markers for alcohol consumption are needed. Carbohydrate-deficient transferrin (CDT) is at present the best available objective measure of drinking behavior. During a withdrawal trial, 92 alcohol-dependent patients who had been admitted to a hospital in an ethanol-intoxicated state were monitored over the following 28 days by using the percent carbohydrate-deficient transferrin (%CDT of total transferrin) (%CDT) method. At the time of admission, 63% showed elevated %CDT levels. After a subsequent period of abstinence, a decrease in %CDT levels was apparent in four different groups of patients, whereas in two groups, comprising the greatest number of patients, normal %CDT levels were evident after 14 days of abstinence. In patients whose CDT levels were very high at study initiation, it took at least 21 to 28 days--and sometimes longer--for CDT to decrease to the radioimmunoassay (RIA) %CDT test cutoff point of 2.5. In a further study of 56 male alcohol-dependent patients, we measured liver enzyme concentrations, mean corpuscular volume (MCV), and four CDT variants on the first day of evidence of withdrawal syndrome. We found a significant correlation between results on the Munich Alcoholism Test (MALT) and MCV levels; among gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels; and among all four CDT variants. A cluster analysis yielded three clusters: (1) GGT, AST, and ALT levels; (2) MCV levels and MALT results; and (3) all CDT measurement variants. We conclude that these three clusters measure different detriments to the patient and that all available CDT variants are commensurate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11839465     DOI: 10.1016/s0741-8329(01)00188-4

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  4 in total

1.  Review of current clinical biomarkers for the detection of alcohol dependence.

Authors:  Hamid R Tavakoli; Michael Hull; Lt Michael Okasinski
Journal:  Innov Clin Neurosci       Date:  2011-03

2.  Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease?

Authors:  Maximilian Schöniger-Hekele; Katrin Ramskogler; Doris Hartl; Otto M Lesch; Christian Müller
Journal:  Wien Med Wochenschr       Date:  2006-04

3.  Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial.

Authors:  Fabio Caputo; Katrin Skala; Antonio Mirijello; Anna Ferrulli; Henriette Walter; Otto Lesch; Giovanni Addolorato
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

4.  Serum Proteomic Profiles In Subjects with Heavy Alcohol Abuse.

Authors:  Suthat Liangpunsakul; Xianyin Lai; Heather N Ringham; David W Crabb; Frank A Witzmann
Journal:  J Proteomics Bioinform       Date:  2009-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.